Skip to main content
. 2022 Apr 9;23(1):46. doi: 10.1186/s10194-022-01396-x

Table 3.

Treatment-emergent adverse event (TEAEs) occurring at weeks 4, 8 and 12

Week 4 Week 8 Week 12
Patients n 60 58 53
Patients with ≥ 1 TEAE 1 (1.7%) 2 (3.4%) 3 (5.7%)
Injection site erythema 1 (1.7%) 1 (1.7%) 1 (1.9%)
Dizziness - 1 (1.7%) -
Abdominal pain - - 1 (1.9%)
Neck pain and somnolence - - 1 (1.0%)
Discontinuation due to TEAEs - - -
Discontinuation due to ineffectiveness - - -